Industry Insight | Cell Therapy Industry Accelerates Shift Toward Industrialized Manufacturing

May 2026 - The cell therapy industry is entering a new phase of commercialization as companies increasingly focus on scalable and automated manufacturing infrastructure. This week, Cabaletta Bio and Cellares announced a 10-year commercial supply agreement to support large-scale manufacturing of rese-cel, an investigational cell therapy for autoimmune diseases.

Under the agreement, manufacturing will utilize Cellares’ automated Cell Shuttle™ platform, which is designed to streamline cell therapy production while reducing labor intensity and manufacturing variability. The companies stated that the platform is intended to support production capacity for thousands of patients per year, reflecting the industry’s growing emphasis on scalable commercialization.

The partnership highlights a broader trend across the cell and gene therapy sector: the transition from small-batch clinical manufacturing toward industrialized cell therapy production. As more therapies advance into late-stage clinical development and commercialization, manufacturing scalability is becoming one of the industry’s most critical competitive factors.

Photo by Talha Hassan on Unsplash

Unlike traditional biologics, cell therapies involve highly complex production workflows, including cell isolation, activation, genetic engineering, expansion, cryopreservation, and quality control. Maintaining consistency across these processes while scaling production remains a major challenge for developers worldwide.

Industry analysts note that technologies enabling automation, standardized workflows, and efficient cell expansion will play an increasingly important role in reducing production costs and improving global access to advanced therapies. This is especially relevant for rapidly growing areas such as CAR-T, CAR-NK, and other next-generation immune cell therapies.

Photo by Trnava University on Unsplash

As manufacturing demands continue to increase, companies specializing in cell expansion platforms and supporting technologies are expected to become increasingly important within the broader cell therapy ecosystem. Providers such as Hillgene Biopharma are supporting this shift through technologies designed for efficient immune cell expansion, including Genetically Modified K562 Feeder Cell platforms used in NK and CAR-NK research and manufacturing workflows.

The industry’s accelerating investment in automation and scalable manufacturing infrastructure suggests that the next stage of competition in cell therapy may depend not only on clinical efficacy, but also on the ability to manufacture therapies reliably, efficiently, and at commercial scale.

Sources:

Cabaletta Bio and Cellares commercial supply agreement announcement

Coverage published by Nasdaq (May 2026)